In November 2025, Cytokinetics announced that additional late-stage aficamten trial data were presented at major cardiovascular conferences, highlighting the drug's positive effects across multiple ...
Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...
Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...
AIOCD asks traders to strictly comply with the ban on 35 FDCs: Peethaambaran Kunnathoor, Chennai Friday, November 21, 2025, ...
Facebook users shared a story claiming a Democratic Party-led "deep state assassination plot" involving the Pennsylvania U.S.
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
Motilal Oswal Financial Services recommends Reliance Industries and HCL Tech from the large-cap basket, while BEL and M&M Financial are top bets from mid-cap ...
A new study published in the journal JAMA has found that a common blood pressure drug may increase the chance of serious ...
Ventricular electrical storm (ES) urgently needs standardized definitions and high-quality evidence to guide diagnosis, risk ...
The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.
Zacks Investment Research on MSN
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Shares of Cytokinetics, Incorporated CYTK have gained 11.4% in a week compared with the industry’s growth of 4.6%. In fact, the stock hit a new 52-week high of $66.98 on Nov. 12, 2025. Image Source: ...
Cytokinetics’ recent earnings call conveyed a mixed sentiment, highlighting both significant achievements and challenges. The company is making notable strides towards the approval and commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback